This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
25I-NBOMe: Difference between revisions
>Unity Attempt at cite error fix. |
>Unity Modified intro to conform to new style standard. |
||
| Line 6: | Line 6: | ||
| ''[[25I-NBOMe/Summary|Summary sheet: 25I-NBOMe]]'' | | ''[[25I-NBOMe/Summary|Summary sheet: 25I-NBOMe]]'' | ||
|} | |} | ||
'''25I-NBOMe''' (also known as '''2C-I-NBOMe''', '''Cimbi-5''' | '''25I-NBOMe''' (also known as '''2C-I-NBOMe''', '''Cimbi-5''' and '''N-Bomb''', although this term might also include other members of the [[25x-NBOMe]] family) is novel synthetic [[Psychoactive class::psychedelic]] of the [[chemical class::Phenethylamine|substituted phenethylamine]] that produces [[Visual effects - Psychedelics|visual-dominant psychedelic effects]] when [[Routes of administration|administered]]. 25I-NBOMe, short-hand for 2C-I-NBOMe, is a derivative of [[2C-I]], first synthesized and documented in 2003 by Ralf Heim at the Free University of Berlin,<ref name="Ralf Heim PhD. (2010-02-28)">Ralf Heim PhD. (2010-02-28) "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 (in German). diss.fu-berlin.de. Retrieved 2013-05-10.</ref> and subsequently investigated by a team at Purdue University led by psychedelics chemist and researcher [[David E. Nichols|David Nichols]].<ref name="Michael Robert Braden PhD. (2007)">Michael Robert Braden PhD. (2007). "Towards a biophysical understanding of hallucinogen action." | http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Purdue University. Retrieved 2012-08-08.</ref> | ||
It is worth noting that compounds of the [[25x-NBOMe|NBOMe]] | It is worth noting that compounds of the [[25x-NBOMe|NBOMe]] family are not [[oral|orally]] active and should, therefore, be taken [[sublingual|sublingually]] by placing the substance into one's mouth and allowing it to absorb over a period of 15-25 minutes. 25I-NBOMe can also be vaporized and inhaled; this may cause significantly quicker effects and shorter duration as is expected from that route of administration. However, this route of administration is not recommended, unless using precise liquid measurement, due to the difficulties of measuring and handling substances active in the microgram range. | ||
In comparison to [[2C-I]], the addition of an NBOMe group to the structure results in a sixteen-fold increase in potency, allowing even the most extreme of dosages to fit in liquid form onto tabs and blotter paper, which people often mistake for [[LSD]]. 25i-NBOMe has a distinctly bitter and metallic taste that [[LSD]] does not have, which can be useful in determining what substance is really on the blotter. | In comparison to [[2C-I]], the addition of an NBOMe group to the structure results in a sixteen-fold increase in potency, allowing even the most extreme of dosages to fit in liquid form onto tabs and blotter paper, which people often mistake for [[LSD]]. 25i-NBOMe has a distinctly bitter and metallic taste that [[LSD]] does not have, which can be useful in determining what substance is really on the blotter. | ||